Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

281 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
EGFR and cancer prognosis.
Nicholson RI, Gee JM, Harper ME. Nicholson RI, et al. Among authors: harper me. Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15. doi: 10.1016/s0959-8049(01)00231-3. Eur J Cancer. 2001. PMID: 11597399 Review.
Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI. Hiscox S, et al. Among authors: harper m. Endocr Relat Cancer. 2006 Dec;13(4):1085-99. doi: 10.1677/erc.1.01270. Endocr Relat Cancer. 2006. PMID: 17158755
Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME, Goddard L, Smith C, Nicholson RI. Harper ME, et al. Prostate. 2004 Jan 1;58(1):13-22. doi: 10.1002/pros.10315. Prostate. 2004. PMID: 14673948
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
Harper ME, Goddard L, Glynne-Jones E, Assender J, Dutkowski CM, Barrow D, Dewhurst OL, Wakeling AE, Nicholson RI. Harper ME, et al. Prostate. 2002 Jun 1;52(1):59-68. doi: 10.1002/pros.10069. Prostate. 2002. PMID: 11992620
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Knowlden JM, et al. Among authors: harper me. Endocrinology. 2003 Mar;144(3):1032-44. doi: 10.1210/en.2002-220620. Endocrinology. 2003. PMID: 12586780
Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.
Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI. Rushmere NK, et al. Among authors: harper me. Int J Cancer. 2004 Mar 1;108(6):930-6. doi: 10.1002/ijc.11606. Int J Cancer. 2004. PMID: 14712499
Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.
Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Among authors: harper me. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S. doi: 10.1158/1078-0432.ccr-031206. Clin Cancer Res. 2004. PMID: 14734490
TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence.
Glynne-Jones E, Harper ME, Seery LT, James R, Anglin I, Morgan HE, Taylor KM, Gee JM, Nicholson RI. Glynne-Jones E, et al. Among authors: harper me. Int J Cancer. 2001 Oct 15;94(2):178-84. doi: 10.1002/ijc.1450. Int J Cancer. 2001. PMID: 11668495
Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.
Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME, Nicholson RI. Jones HE, et al. Among authors: harper me. Prostate. 2001 Sep 15;49(1):38-47. doi: 10.1002/pros.1116. Prostate. 2001. PMID: 11550209
Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI. Harper ME, et al. J Pathol. 1998 Oct;186(2):169-77. doi: 10.1002/(SICI)1096-9896(1998100)186:2<169::AID-PATH164>3.0.CO;2-W. J Pathol. 1998. PMID: 9924433
281 results
Jump to page